Stromal biology and therapy in pancreatic cancer: a changing paradigm (Q38494338)

3 September 2017

1 reference

title

Stromal biology and therapy in pancreatic cancer: a changing paradigm (English)

1 reference

3 September 2017

1 reference

Hana Algül

2

0 references

Thomas Gress

object named as

Thomas M Gress

series ordinal

4

0 references

David Tuveson

series ordinal

3

object named as

David A Tuveson

1 reference

3 September 2017

Albrecht Neesse

1

1 reference

3 September 2017

language of work or name

English

0 references

publication date

20 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

64

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

1476-1484

1 reference

3 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

The pancreas cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Stromal biology and therapy in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Pancreatic cancer-associated stroma production

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

The role of stroma in pancreatic cancer: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

What we have learned about pancreatic cancer from mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Pancreatic cancer stroma: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Genetics and biology of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Fibroblast heterogeneity in the cancer wound

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Maximizing mouse cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

A modular and flexible ESC-based mouse model of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Translational therapeutics in genetically engineered mouse models of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Quantification of murine pancreatic tumors by high-resolution ultrasound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Organoid models of human and mouse ductal pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Mortality, cancer, and comorbidities associated with chronic pancreatitis: a Danish nationwide matched-cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

The immune network in pancreatic cancer development and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Pancreatic stellate cells: partners in crime with pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Immune infiltrates as predictive markers of survival in pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Tumor-associated macrophages: functional diversity, clinical significance, and open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Tumor associated macrophages and neutrophils in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

CUX1 modulates polarization of tumor-associated macrophages by antagonizing NF-κB signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Accessories to the crime: functions of cells recruited to the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Cancer immunology and cancer immunodiagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Combining two strategies to improve perfusion and drug delivery in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Stromal reengineering to treat pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Transport properties of pancreatic cancer describe gemcitabine delivery and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

21 January 2018

Fibroblasts in cancer

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2015-309304

10.1136/GUTJNL-2015-309304

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference